Abstract

Objective: Cystic fibrosis (CF) is an inherited disorder which has negative impact on life span and quality. Newbornscreening (NBS) is carried out by sweat chloride test (SCT) in babies with high immunoreactive trypsinogen (IRT) values.We aimed to present our data consisting of application and evaluation of sweat chloride test in babies referred to ourcenter with two elevated IRT levels following national NBS.

Material and Methods: This retrospective study evaluated clinical data, sweat chloride test and CF transmembraneregulator (CFTR) gene mutation analysis results of referred infants due to positive CF NBS between January 2015–January 2019. Sweat chloride test results were interpreted as normal (<30mmol/L), intermediate (30-59 mmol/L) or high(≥60mmol/L). Infants missing a second test despite an initial invalid result (<10 mmol/L) or inadequate sweat collectionwere not included.

Results: The study group consisted of 184 infants of female/male ratio as 113/71(61.4/38.6%). The median admissiontime was postnatal 26 (9-98) days. The mean gestational week was 39 ± 1.75 weeks and mean birth weight was 3300± 432 grams. All infants passed their first stool in 48 hours at most. Five infants (3.6%) faced prolonged jaundice andtwo (1.4%) had neonatal pneumonia. Weight gain was insufficient in seven (5%) infants. No infant showed physicalexamination findings consistent with CF. First SCT was normal (n=153, 83.1%), intermediate (n=9, 4.9%) or high (n=1,0.5%). Thirty-one infants had the second test because of inadequate sweat collection, invalid or high/intermediaterange initial result. Consequently, 178 infants (96.7%) reflected normal results. Repeated SCT was high (n=2, 1.1%)/intermediate (n=4, 2.2%) in six (3.3%) infants. CFTR mutation analysis revealed one homozygote F508 deletion andthree 5T/7T/9T polymorphisms. Three patients received treatment while three were conservatively followed-up.

Conclusion: NBS can provide early diagnosis of patients with CF if standardized implementation and careful interpretationof sweat chloride test are achieved. Sharing of data by centers performing sweat chloride test is extremely important for the assurance of interoperability of the system.

Keywords: cystic fibrosis, neonatal screening

References

  1. Boyle MP, De Boeck K. A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. Lancet Respir Med 2013;1:158-63.
  2. Cystic Fibrosis Mutation Database. http://www.genet.sickkids.on.ca/Home.htlm2013. Accessed Jan 14, 2019.
  3. Southern KW, Munck A, Pollitt R, Travert G, Zanolla L, Dankert-Roelse J, et al. A survey of newborn screening for cystic fibrosis in Europe. J Cyst Fibros 2007;6:57–65.
  4. Gürson CT, Sertel H, Gürkan M, Pala S. Newborn screening for cystic fibrosis with the chloride electrode and neutron activation analysis. Helv Paediatr Acta 1973;28:165-74
  5. T.C. Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu Ulusal Yenidoğan Tarama Programı Kistik Fibrozis Taraması Ter Testi Rehberi 2015
  6. Paranjape SM, Mogayzel PJ Jr. Cystic fibrosis. Pediatr Rev 2014;35:194-205.
  7. Türk Toraks Derneği Kistik Fibrozis Tanı ve Tedavi Rehberi. Türk Toraks Dergisi 2011; 12:2. https://www.toraks.org.tr/book.aspx?list=1078&menu=222&menu=222
  8. Farrell PM, White TB, Howenstine MS, Munck A, Parad RB, Rosenfeld M, et al. Diagnosis of Cystic Fibrosis in Screened Populations. J Pediatr 2017;181S:S33-S44.e2.
  9. Cystic Fibrosis Foundation. 2012 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation Patient Registry; 2013.
  10. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report.3rd; Cystic Fibrosis Foundation.J Pediatr 2008;153:S4-S14.
  11. Rosenfeld M, Sontag MK, Ren CL. Cystic Fibrosis Diagnosis and Newborn Screening.Pediatr Clin North Am 2016;63:599-615.
  12. Southern KW, Merelle MM, Dankert-Roelase JE, Nagelkerke AD. Newborn screening for cystic fibrosis. Cochrane Database Syst Rev 2009; 1: CD001402.
  13. Therrell BL Jr, Hannon WH, Hoffman G, Ojodu J, Farrell PM. Immunoreactive Trypsinogen (IRT) as a Biomarker for Cystic Fibrosis: challenges in newborn dried blood spot screening. Mol Genet Metab 2012;106:1-6.
  14. T.C. Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu. Kistik fibrozis yenidoğan tarama testi ile tanı alan hastaları izleme rehberi, 2015 (Çocuk Solunum Yolu Hastalıkları ve Kistik Fibrozis Derneği, Çocuk Göğüs Hastalıkları Derneği) http://kistikfibrozisturkiye.org/2017/files/admin/KF_yenidogan_tarama_rehberi.pdf
  15. Gibson Le, Cooke Re. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 1959;23:545-9.
  16. Crossley JR, Elliott RB, Smith PA. Dried-blood spot screening for cystic fibrosis in the newborn. Lancet 1979;1:472-4.
  17. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry 2014 annual data report. Bethesda (MD): Cystic Fibrosis Foundation; 2015. https://www.cff.org/Our-Research/CF-Patient-Registry/2015-Patient-Registry-Annual-Data-Report.pdf
  18. Cystic fibrosis Trust. UK Cystic Fibrosis Registry annual data report 2016. 2017. https://www.cysticfibrosis.org.uk/the-work-we-do/uk-cf-registry/reporting-and-resources.
  19. Castellani C, Massie J, Sontag M, Southern KW. Newborn screening for cystic fibrosis. Lancet Respir Med 2016;4:653-61.
  20. McColley SA, Michelson P, Petren K. A state level registry report for assesssment of cystic fibrosis newborn screening programs. Pediatr Pulmonol 2014;49: S383.
  21. Groves T, Robinson P, Fitzgerald DA. Question 7: For an infant with an equivocal sweat chloride following newborn screening, how likely is a diagnosis of cystic fibrosis? Paediatr Respir Rev 2016;20:48-50.
  22. Salinas DB, Azen C, Young S, Keens TG, Kharrazi M, Parad RB. Phenotypes of California CF Newborn Screen-Positive Children with CFTR 5T Allele by TG Repeat Length. Genet Test Mol Biomarkers 2016;20:496-503.

Copyright and license

Copyright © 2019 The Author(s). This is an open access article distributed under the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Çullas İlarslan NE, Özcan G, Yıldırım DN, Günay F, Çobanoğlu N. Evaluation of patients referred following cystic fibrosis newborn screening: Four year experience of a single-center. Turk J Pediatr Dis [Internet]. 2019 Jul. 30 [cited 2025 Aug. 23];13(4):270-6. Available from: https://turkjpediatrdis.org/article/view/592